Anavex Life Sciences Management
Management criteria checks 4/4
Anavex Life Sciences' CEO is Chris Missling, appointed in Jul 2013, has a tenure of 11.42 years. total yearly compensation is $2.78M, comprised of 25.1% salary and 74.9% bonuses, including company stock and options. directly owns 1.47% of the company’s shares, worth $13.59M. The average tenure of the management team and the board of directors is 2.9 years and 10.6 years respectively.
Key information
Chris Missling
Chief executive officer
US$2.8m
Total compensation
| CEO salary percentage | 25.1% |
| CEO tenure | 11.4yrs |
| CEO ownership | 1.5% |
| Management average tenure | 2.9yrs |
| Board average tenure | 10.6yrs |
Recent management updates
Recent updates
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
Dec 25
Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis
Dec 24Anavex: EU Approval Application Is A Precipitous Moment
Dec 08Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Nov 11Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Nov 05Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Oct 08Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Jul 29Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Jul 17Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | US$3m | US$700k | -US$43m |
| Jun 30 2024 | n/a | n/a | -US$42m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | n/a | n/a | -US$43m |
| Sep 30 2023 | US$4m | US$700k | -US$48m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$53m |
| Dec 31 2022 | n/a | n/a | -US$50m |
| Sep 30 2022 | US$7m | US$586k | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$45m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | n/a | n/a | -US$41m |
| Sep 30 2021 | US$9m | US$550k | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | n/a | n/a | -US$28m |
| Sep 30 2020 | US$2m | US$550k | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | n/a | n/a | -US$26m |
| Sep 30 2019 | US$3m | US$513k | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$26m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | n/a | n/a | -US$20m |
| Sep 30 2018 | US$3m | US$500k | -US$17m |
Compensation vs Market: Chris's total compensation ($USD2.78M) is about average for companies of similar size in the US market ($USD3.22M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Missling (58 yo)
11.4yrs
Tenure
US$2,783,700
Compensation
Dr. Christopher U. Missling, also known as the Chris, MS, Ph D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and also serves as its Director an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 11.4yrs | US$2.78m | 1.47% $ 13.6m | |
| Principal Financial Officer & Treasurer | 9.2yrs | US$402.23k | 0.027% $ 249.6k | |
| Chief Scientific Officer | 2.9yrs | no data | no data | |
| VP of Corporate | no data | no data | no data | |
| Senior Vice President of Nonclinical Development | 3.6yrs | no data | no data | |
| Chief Medical Officer | 2.9yrs | no data | no data | |
| Head of Biostatistics | 1.8yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | 1.1yrs | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data | |
| Senior VP & Head of Research and Development | less than a year | no data | no data |
2.9yrs
Average Tenure
Experienced Management: AVXL's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 11.4yrs | US$2.78m | 1.47% $ 13.6m | |
| Independent Chairman | 3.6yrs | US$243.20k | no data | |
| Member of the Scientific Advisory Board | 9.8yrs | no data | no data | |
| Member of the Scientific Advisory Board | 13.8yrs | no data | no data | |
| Member of the Scientific Advisory Board | 11yrs | no data | no data | |
| Member of the Scientific Advisory Board | 11.1yrs | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 11.9yrs | US$227.20k | 1.54% $ 14.2m | |
| Member of the Scientific Advisory Board | 10.6yrs | no data | no data | |
| Member of the Scientific Advisory Board | 9.8yrs | no data | no data | |
| Independent Director | 9.5yrs | US$227.20k | 0.0059% $ 54.4k | |
| Lead Independent Director | 6.8yrs | US$243.20k | no data |
10.6yrs
Average Tenure
58yo
Average Age
Experienced Board: AVXL's board of directors are seasoned and experienced ( 10.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 22:42 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anavex Life Sciences Corp. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Yun Zhong | BTIG |
| Charles Duncan | Cantor Fitzgerald & Co. |